The live cell encapsulation market has experienced significant advancements driven by emerging technologies in the biopharmaceuticals sector. In 2021, researchers at the Massachusetts Institute of Technology developed a method to encapsulate live cells within hydrogel materials, enhancing their viability and functional stability. This technological shift has enabled wider applications in drug delivery systems, particularly for chronic diseases. Additionally, companies such as Corium International have focused on creating encapsulated cell therapies for better treatment efficiencies, leading to increased academic collaborations. The rise in nanoparticle technology, particularly in 2022, has also contributed to improvements in the biocompatibility of encapsulation materials. In Europe, regulatory bodies like the European Medicines Agency (EMA) have established guidelines in 2023 for the safety evaluation of such biopharmaceuticals, promoting research efforts in encapsulated cell applications. Companies are also exploring 3D bioprinting techniques, as seen in the work by Organovo Holdings, which integrates cell encapsulation methods for organ manufacturing. Furthermore, global health initiatives, such as the World Health Organization's focus on cellular therapies for regenerative medicine in 2022, have spurred investment in encapsulated technology for therapeutic purposes. As research progresses, the trend toward multifunctional encapsulation methods, which can simultaneously deliver drugs and provide protective environments for cells, is gaining traction and reflects broader shifts in cellular therapy paradigms.
